GENENTECH GETS APPROVAL FOR AVASTIN TO TREAT LUNG CANCER -- UPDATE

Wednesday, Genentech, Inc., revealed U.S. Food and Drug Administration approval for its Avastin (bevacizumab) indicated as a first line treatment for patients with inoperable, recurrent or metastatic non-squamous, non-small cell lung cancer. The FDA approved Avastin in combination with carboplatin and paclitaxel chemotherapy, based on results from a Phase III study. Trading Markets (http://www.tradingmarkets.com/.site/news/BREAKING%20NEWS/453426/)